CNA Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

CNA Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,516	Closed	-$228K	–	165
2022 Q3	$228K	Sell	10,516 -1,170	-10%	-$32K	0.09%	158
2022 Q2	$328K	Buy	11,686 +3,510	+43%	+$93K	0.11%	155
2022 Q1	$377K	Buy	8,176 +220	+3%	+$11.9K	0.12%	164
2021 Q4	$669K	Sell	7,956 -1,410	-15%	-$109K	0.17%	137
2021 Q3	$624K	Buy	9,366 +300	+3%	+$17.3K	0.17%	150
2021 Q2	$482K	Sell	9,066 -2,380	-21%	-$127K	0.14%	166
2021 Q1	$497K	Buy	11,446 +2,680	+31%	+$115K	0.15%	159
2020 Q4	$455K	Buy	8,766 +380	+5%	+$17.1K	0.14%	168
2020 Q3	$274K	Buy	8,386 +2,960	+55%	+$104K	0.1%	173
2020 Q2	$261K	Buy	+5,426	New	+$208K	0.1%	166

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

CNA Financial's ZNTL Position: Q4 2022 in Review

CNA Financial sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2022, closing a stake of 10,516 shares — an estimated $228K sold.

CNA Financial first reported a position in ZNTL in Q2 2020 and held it in 10 quarters. The position peaked at $669K in Q4 2021. 106 funds tracked by Wall St. Rank hold ZNTL as of Q4 2022.

CNA Financial reported no remaining Zentalis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
CNA Financial sold 10,516 Zentalis Pharmaceuticals shares in Q4 2022, an estimated $228K.
CNA Financial first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 10 quarters.
CNA Financial's Zentalis Pharmaceuticals position peaked at $669K in Q4 2021.
106 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2022.

Based on CNA Financial's 13F filing for Q4 2022, filed 10 Feb 2023.